机译:与甲氨蝶呤相关的比较癌症风险,其他非生物学和生物疾病改性抗风湿药物
Division of Rheumatology Immunology and Allergy Brigham and Women's Hospital Boston MA United;
Division of Rheumatology Albany Medical College Albany NY United States;
Division of Rheumatology Massachusetts General Hospital Boston MA United States;
Division of Clinical Immunology and Rheumatology University of Alabama at Birmingham Birmingham;
Clinical Trials Unit Division of Rheumatology New York University School of Medicine New York;
Division of Rheumatology University of Massachusetts Medical School Worcester MA United States;
Division of Rheumatology and Clinical Immunology Department of Medicine and Division of;
Department of Biostatistics University of Massachusetts Medical Center Worcester MA United;
Division of Rheumatology Immunology and Allergy Brigham and Women's Hospital Boston MA United;
Clinical Trials Unit Division of Rheumatology New York University School of Medicine New York;
Cancer; DMARDs; Epidemiology; Methotrexate; Rheumatoid arthritis;
机译:与甲氨蝶呤,其他非生物和生物疾病改良抗风湿药相关的癌症风险比较
机译:BSR和BHPR的处方和监测非生物疾病改性抗风湿药物的指导方针
机译:BSR和BHPR的处方和监测非生物疾病改性抗风湿药物的指导方针
机译:IG-001—用于治疗转移性乳腺癌的非生物胶束紫杉醇制剂
机译:药物敏感性和耐药性人MCF-7乳腺癌细胞线粒体蛋白质的比较蛋白质组学分析。
机译:评论:BSR和BHPR指南用于非生物疾病改良抗风湿药的处方和监测
机译:LB0001 uPAdacitinib的疗效和安全性与安慰剂和Adalimalab有活跃的银屑病关节炎,对非生物疾病改性抗风湿药物的反应不足(选择-PSA-1):双盲随机控制第3阶段试验